Cargando...
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials
PURPOSE: PARP inhibition is an exciting new anticancer strategy. As the first PARP inhibitor approved for the treatment of advanced BRCA-mutated ovarian cancer, olaparib has proven to be effective in the treatment of several solid tumors. We performed a meta-analysis of published randomized controll...
Gardado en:
| Publicado en: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6089112/ https://ncbi.nlm.nih.gov/pubmed/30127642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S169558 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|